N. El Saghir Et Al. , "Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2-inoperable locally advanced or metastatic breast cancer: RIGHT choice study," 44th Congress of the European-Society-for-Medical-Oncology (ESMO) , Barcelona, Spain, pp.140-141, 2019
El Saghir, N. Et Al. 2019. Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2-inoperable locally advanced or metastatic breast cancer: RIGHT choice study. 44th Congress of the European-Society-for-Medical-Oncology (ESMO) , (Barcelona, Spain), 140-141.
El Saghir, N., Malwinder, S., Azim, H., Eralp, Y., Im, S., Yap, Y. S., ... Alfaro, T. D.(2019). Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2-inoperable locally advanced or metastatic breast cancer: RIGHT choice study . 44th Congress of the European-Society-for-Medical-Oncology (ESMO) (pp.140-141). Barcelona, Spain
El Saghir, N. Et Al. "Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2-inoperable locally advanced or metastatic breast cancer: RIGHT choice study," 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 2019
El Saghir, N. E. Et Al. "Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2-inoperable locally advanced or metastatic breast cancer: RIGHT choice study." 44th Congress of the European-Society-for-Medical-Oncology (ESMO) , Barcelona, Spain, pp.140-141, 2019
El Saghir, N. Et Al. (2019) . "Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2-inoperable locally advanced or metastatic breast cancer: RIGHT choice study." 44th Congress of the European-Society-for-Medical-Oncology (ESMO) , Barcelona, Spain, pp.140-141.
@conferencepaper{conferencepaper, author={N. El Saghir Et Al. }, title={Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2-inoperable locally advanced or metastatic breast cancer: RIGHT choice study}, congress name={44th Congress of the European-Society-for-Medical-Oncology (ESMO)}, city={Barcelona}, country={Spain}, year={2019}, pages={140-141} }